CLINICAL TRIALS PROFILE FOR HEPLISAV-B

All Clinical Trials for HEPLISAV-B

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03934736 ↗	HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis	Active, not recruiting	Dynavax Technologies Corporation	Phase 1	2019-04-29	This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.
NCT04843852 ↗	TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B	Not yet recruiting	University of Maryland, Baltimore	Phase 1	2021-12-01	Unmethylated cystine-guanosine dinucleotide (CpG) motifs are pathogen-associated molecular patterns (PAMPs) associated with bacterial and viral-derived DNA that activate the innate and humoral immunity via toll-like receptor 9. This is a randomized controlled pilot study evaluating the clinical and immune correlates of a seroprotective immune response against a CpG-adjuvanted vaccine for hepatitis B.

Clinical Trial Conditions for HEPLISAV-B

Condition Name

Condition Name for HEPLISAV-B
Intervention	Trials
Hepatitis B	1
End Stage Renal Disease on Dialysis (Diagnosis)	1

Condition MeSH

Condition MeSH for HEPLISAV-B
Intervention	Trials
Hepatitis B	2
Hepatitis	1
Kidney Failure, Chronic	1

Clinical Trial Locations for HEPLISAV-B

Trials by Country

Trials by Country for HEPLISAV-B
Location	Trials
United States	17

Trials by US State

Trials by US State for HEPLISAV-B
Location	Trials
Virginia	2
Maryland	1
Wisconsin	1
Texas	1
Pennsylvania	1

Clinical Trial Progress for HEPLISAV-B

Clinical Trial Phase

Clinical Trial Phase for HEPLISAV-B
Clinical Trial Phase	Trials
Phase 1	2

Clinical Trial Status

Clinical Trial Status for HEPLISAV-B
Clinical Trial Phase	Trials
Not yet recruiting	1
Active, not recruiting	1

Clinical Trial Sponsors for HEPLISAV-B

Sponsor Name

Sponsor Name for HEPLISAV-B
Sponsor	Trials
Dynavax Technologies Corporation	1
University of Maryland, Baltimore	1

Sponsor Type

Sponsor Type for HEPLISAV-B
Sponsor	Trials
Industry	1
Other	1